Google
BFRG — BULLFROG AI HOLDINGS, INC. COMMON STOCK (Healthcare >> Health Information Services)
BFRG FAQ
What is BFRG's ROE?
BULLFROG AI HOLDINGS, INC. COMMON STOCK reports a Return on Equity (ROE) of -124.29%.
What is BFRG's dividend yield?
BULLFROG AI HOLDINGS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is BFRG's Deepscope Quality Score?
Deepscope rates BFRG's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BFRG?
Deepscope's AI Timing Score for BFRG is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BFRG belong to?
BULLFROG AI HOLDINGS, INC. COMMON STOCK is classified under the Healthcare >> Health Information Services sector on the NASDAQ exchange.
|
USD 0.67
Price
-0.10
(-12.82%)
Day Change
|
|
|---|
BFRG, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 82 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.67 |
| PBV / Sector |
2.92 / 4.52
|
| Earning Per Share | -0.29 |
| PE / Sector |
N/A / 45.70
|
| PEG or PE/Growth / Sector |
N/A / -0.26
|
| Average 1M Daily Value |
0.22 M
GREAT
|
| Average 1W Daily Value |
0.20 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:27 |
| Symbol | BFRG |
| Name | BULLFROG AI HOLDINGS, INC. COMMON STOCK |
| Sector | Healthcare >> Health Information Services |
| Market | NASDAQ |
| Listed Shares | 18.54 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 14.28 / 3,839.73 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 325 Ellington Boulevard, Gaithersburg, MD, United States, 20878
Phone: 240 658 6710
Website: https://www.bullfrogai.com
Description: Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
ME vs SECTOR Healthcare >> Health Information Services
Click a bubble to view stock details · Bubble size represents market capitalization share
